Soluble Epoxide Hydrolase Inhibitor TPPU Alleviates Nab-Paclitaxel-Induced Peripheral Neuropathic Pain via Suppressing NF-κB Signalling in the Spinal Cord of a Rat

This study investigates the role of soluble epoxide hydrolase (sEH) inhibition in paclitaxel-induced peripheral neuropathy (PIPN) in rats. It explores whether the sEH inhibitor TPPU can alleviate PIPN symptoms. The research involves creating a rat model of PIPN using nab-paclitaxel and then administering TPPU to assess its effects on various factors like pain thresholds, apoptosis, glial activation, axonal injury, and blood-spinal cord barrier permeability. The findings suggest that TPPU can relieve PIPN by inhibiting the activation of the sEH and NF-κB signaling pathways, reducing inflammation, and decreasing oxidative stress in the spinal cord.

• 1
  TPPU restored mechanical and thermal thresholds in rats treated with nab-paclitaxel, indicating pain relief.
• 2
  TPPU decreased cell apoptosis, alleviated axonal injury and glial responses, and protected vascular permeability in the spinal cord.
• 3
  TPPU relieved PIPN by inhibiting the activation of the sEH and NF-κB signalling pathways by decreasing the levels of infammatory cytokines and oxidative stress.